MacuSight Inc.

Otonomy Inc. is tackling a group of underserved middle and inner ear disorders with a platform of known drugs incorporated into a slow-release polymer gel that could replace multiple injections thro

The original victim of Lucentis' (ranibizumab) efficacy, Pfizer's Macugen, has been officially withdrawn from development in diabetic macular oedema, months after Pfizer handed back another DMO projec

Ophthalmology has long been the darling of venture investors who seem unlikely to avert their gaze thanks to the therapeutic area's big markets, medical necessity, and an enlarged list of potential ac

MacuSight (US) has named Gerald Wroblewski vice-president of operations. He previously served as chief operating officer at the start-up medical device company iScience Interventional. MacuSight i